DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/hk7gkr/metastatic) has announced the addition of the "Metastatic Ovarian Cancer - Pipeline Review, H2 2015" report to their offering.
This report provides comprehensive information on the therapeutic development for Metastatic Ovarian Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Metastatic Ovarian Cancer and special features on late-stage and discontinued projects.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Companies Involved in Therapeutics Development
- Cellceutix Corporation
- Eisai Co., Ltd.
- F. Hoffmann-La Roche Ltd.
- Immune Design Corp.
- Millennium Pharmaceuticals, Inc.
- Natco Pharma Limited
- Northwest Biotherapeutics, Inc.
- Sumitomo Dainippon Pharma Co., Ltd.
VG Life Sciences, Inc.
- Drugs for Metastatic Ovarian Cancer
- hydroxychloroquine + sorafenib tosylate
- Vaccine for Oncology
For more information visit http://www.researchandmarkets.com/research/hk7gkr/metastatic